Vanda Pharmaceuticals Q1 2026 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: seekingalpha
- Disappointing Earnings: Vanda Pharmaceuticals reported a Q1 2026 GAAP EPS of -$0.82, missing expectations by $0.13, indicating challenges in profitability that could undermine investor confidence.
- Slight Revenue Growth: The company achieved revenue of $51.7 million in Q1, a 3.3% year-over-year increase, yet fell short of expectations by $1.2 million, suggesting pressure in market competition and the need for enhanced sales strategies.
- Deteriorating Cash Position: As of March 31, 2026, Vanda's cash and cash equivalents totaled $202.3 million, a decrease of $61.5 million in Q1, which included a one-time $10 million milestone payment to Eli Lilly, reflecting tight cash management.
- Upgraded 2026 Financial Guidance: Vanda raised its total revenue guidance for 2026 to $240 million to $290 million, reflecting contributions from the newly launched NEREUS™ product, while maintaining previous guidance for Fanapt® and other products, demonstrating confidence in the new product's market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.230
Low
7.50
Averages
13.63
High
22.00
Current: 6.230
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Receives FDA Rare Pediatric Disease Designation
- FDA Designation Progress: Vanda Pharmaceuticals announced that its investigational therapy VCA-894A for Charcot-Marie-Tooth disease type 2S has received Rare Pediatric Disease Designation from the FDA, aimed at encouraging the development of treatments for serious rare diseases, highlighting significant unmet medical needs in this area.
- Disease Background: CMT2S is a rare inherited neurological disorder with a global prevalence of less than 1 in 1,000,000, leading to progressive loss of motor function; the FDA's designation underscores the severe impact of this disease on pediatric patients, further propelling Vanda's research efforts.
- Therapeutic Potential: VCA-894A is an antisense oligonucleotide targeting a specific genetic variant, aiming to provide potentially transformative treatment for CMT2S patients, with Vanda's CEO stating that the development of this drug brings hope to patients and families, addressing existing treatment gaps.
- Priority Review Mechanism: Under the FDA's Rare Pediatric Disease Priority Review Voucher program, Vanda may have the opportunity to receive a priority review voucher in the future, which would expedite the approval process for its marketing application, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Vanda Pharmaceuticals Receives FDA Rare Pediatric Disease Designation
- FDA Designation Impact: Vanda Pharmaceuticals' experimental therapy VCA-894A has received FDA Rare Pediatric Disease Designation, making it eligible for a priority review voucher that could expedite its market entry, addressing urgent medical needs for pediatric patients.
- Therapy Development Progress: The therapy targets a specific genetic mutation linked to Charcot-Marie-Tooth disease type 2S, with Vanda planning to work closely with the FDA to advance its development, aiming to provide potentially transformative treatment options for affected patients.
- Positive Market Reaction: Following the announcement of the designation, Vanda's shares rose 1% in after-hours trading, reflecting investor optimism about the company's future prospects, particularly in the niche market for rare disease treatments.
- Analyst Ratings Optimistic: According to Koyfin data, 75% of analysts covering VNDA rate it as a 'Buy', with a 12-month price target of $14.13, indicating a potential upside of about 121% from the current stock price, despite the stock's 28% decline year-to-date.
See More
Vanda Pharmaceuticals Receives FDA Rare Drug Designation
- FDA Rare Drug Designation: Vanda Pharmaceuticals announced that its product has received Rare Drug Designation from the FDA, which will provide the company with greater market opportunities and funding support during drug development.
- Market Potential Enhancement: With the Rare Drug Designation, Vanda can enjoy a longer market exclusivity period, which will help enhance its position in the highly competitive pharmaceutical market.
- R&D Investment Returns: This designation may attract more investor attention to Vanda's R&D projects, thereby providing financial backing for the company's future innovative drug development.
- Strategic Development Direction: This advancement indicates Vanda's ongoing commitment to the rare disease sector, which is expected to drive further growth and market expansion for the company in this area.
See More
Vanda Receives FDA Rare Pediatric Disease Designation
- FDA Designation: Vanda Pharmaceuticals' VCA-894A has received FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease type 2S (CMT2S), a rare and serious inherited neurological disorder, highlighting the drug's importance in addressing significant unmet medical needs for patients.
- Disease Context: CMT2S has an estimated prevalence of less than 1 in 1,000,000 worldwide, primarily affecting children and leading to muscle weakness and loss of motor function, with the FDA's designation underscoring the severity of the disease and its impact on patients' quality of life.
- Therapeutic Potential: VCA-894A is an antisense oligonucleotide targeting a specific genetic variant, potentially offering new treatment options for CMT2S patients; Vanda's CEO noted that this designation supports efforts to develop a potentially transformative therapy.
- Priority Review Mechanism: Following the Rare Pediatric Disease Designation, Vanda may become eligible for a priority review voucher, which would expedite the approval process for its marketing application, thereby supporting the company's future growth and innovation.
See More
Vanda Pharmaceuticals Receives Orphan Drug Designation in Japan
- Orphan Drug Designation: Vanda Pharmaceuticals announced that its drug Imsidolimab has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare, aimed at treating generalized pustular psoriasis, a rare autoinflammatory disease that can lead to severe complications if untreated.
- Patient Impact: Approximately 2,200 individuals in Japan are affected by generalized pustular psoriasis, and Imsidolimab is designed to inhibit interleukin-36 (IL-36) receptor signaling, addressing the deficiency of the endogenous IL-36 receptor antagonist observed in patients, thereby improving their quality of life.
- Market Exclusivity: With orphan drug designation, Vanda will benefit from up to 10 years of market exclusivity and subsidies for research and development costs, significantly lowering its barriers to entry in the Japanese market and enhancing its profit potential.
- Stock Market Reaction: Vanda's stock closed up 3.86% at $6.46 on Wednesday, with after-hours trading showing a further increase of 1.24% to $6.54, reflecting positive market expectations regarding the drug's prospects.
See More
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Vanda Pharmaceuticals will participate in three significant investor conferences in May 2026, including the Bank of America Securities Global Health Care Conference on May 12 in Las Vegas, showcasing its latest advancements in the biopharmaceutical sector to attract more investor interest.
- Conference Details: At the HCW 4th Annual BioConnect Investor Conference on May 19, Vanda will hold a fireside chat at 2:00 p.m. Eastern Time, expected to discuss the company's strategic direction and future development plans, thereby enhancing investor confidence.
- Live Streaming Access: Investors can access the fireside chat live on Vanda's corporate website during the HCW conference, emphasizing the company's commitment to transparency and investor relations by advising attendees to register and download necessary software 15 minutes prior to the event.
- Long-term Development Vision: Vanda Pharmaceuticals focuses on developing innovative therapies to address unmet medical needs, and participating in these conferences not only helps raise the company's profile but also lays the groundwork for its future commercialization strategy, driving sustained growth in the biopharmaceutical industry.
See More
Vanda Receives FDA Rare Pediatric Disease Designation
- FDA Designation Progress: Vanda Pharmaceuticals announced that its investigational therapy VCA-894A for Charcot-Marie-Tooth disease type 2S has received Rare Pediatric Disease Designation from the FDA, aimed at encouraging the development of treatments for serious rare diseases, highlighting significant unmet medical needs in this area.
- Disease Background: CMT2S is a rare inherited neurological disorder with a global prevalence of less than 1 in 1,000,000, leading to progressive loss of motor function; the FDA's designation underscores the severe impact of this disease on pediatric patients, further propelling Vanda's research efforts.
- Therapeutic Potential: VCA-894A is an antisense oligonucleotide targeting a specific genetic variant, aiming to provide potentially transformative treatment for CMT2S patients, with Vanda's CEO stating that the development of this drug brings hope to patients and families, addressing existing treatment gaps.
- Priority Review Mechanism: Under the FDA's Rare Pediatric Disease Priority Review Voucher program, Vanda may have the opportunity to receive a priority review voucher in the future, which would expedite the approval process for its marketing application, enhancing the company's competitiveness in the biopharmaceutical sector.
See More
Vanda Pharmaceuticals Receives FDA Rare Pediatric Disease Designation
- FDA Designation Impact: Vanda Pharmaceuticals' experimental therapy VCA-894A has received FDA Rare Pediatric Disease Designation, making it eligible for a priority review voucher that could expedite its market entry, addressing urgent medical needs for pediatric patients.
- Therapy Development Progress: The therapy targets a specific genetic mutation linked to Charcot-Marie-Tooth disease type 2S, with Vanda planning to work closely with the FDA to advance its development, aiming to provide potentially transformative treatment options for affected patients.
- Positive Market Reaction: Following the announcement of the designation, Vanda's shares rose 1% in after-hours trading, reflecting investor optimism about the company's future prospects, particularly in the niche market for rare disease treatments.
- Analyst Ratings Optimistic: According to Koyfin data, 75% of analysts covering VNDA rate it as a 'Buy', with a 12-month price target of $14.13, indicating a potential upside of about 121% from the current stock price, despite the stock's 28% decline year-to-date.
See More
Vanda Pharmaceuticals Receives FDA Rare Drug Designation
- FDA Rare Drug Designation: Vanda Pharmaceuticals announced that its product has received Rare Drug Designation from the FDA, which will provide the company with greater market opportunities and funding support during drug development.
- Market Potential Enhancement: With the Rare Drug Designation, Vanda can enjoy a longer market exclusivity period, which will help enhance its position in the highly competitive pharmaceutical market.
- R&D Investment Returns: This designation may attract more investor attention to Vanda's R&D projects, thereby providing financial backing for the company's future innovative drug development.
- Strategic Development Direction: This advancement indicates Vanda's ongoing commitment to the rare disease sector, which is expected to drive further growth and market expansion for the company in this area.
See More
Vanda Receives FDA Rare Pediatric Disease Designation
- FDA Designation: Vanda Pharmaceuticals' VCA-894A has received FDA Rare Pediatric Disease Designation for Charcot-Marie-Tooth disease type 2S (CMT2S), a rare and serious inherited neurological disorder, highlighting the drug's importance in addressing significant unmet medical needs for patients.
- Disease Context: CMT2S has an estimated prevalence of less than 1 in 1,000,000 worldwide, primarily affecting children and leading to muscle weakness and loss of motor function, with the FDA's designation underscoring the severity of the disease and its impact on patients' quality of life.
- Therapeutic Potential: VCA-894A is an antisense oligonucleotide targeting a specific genetic variant, potentially offering new treatment options for CMT2S patients; Vanda's CEO noted that this designation supports efforts to develop a potentially transformative therapy.
- Priority Review Mechanism: Following the Rare Pediatric Disease Designation, Vanda may become eligible for a priority review voucher, which would expedite the approval process for its marketing application, thereby supporting the company's future growth and innovation.
See More
Vanda Pharmaceuticals Receives Orphan Drug Designation in Japan
- Orphan Drug Designation: Vanda Pharmaceuticals announced that its drug Imsidolimab has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare, aimed at treating generalized pustular psoriasis, a rare autoinflammatory disease that can lead to severe complications if untreated.
- Patient Impact: Approximately 2,200 individuals in Japan are affected by generalized pustular psoriasis, and Imsidolimab is designed to inhibit interleukin-36 (IL-36) receptor signaling, addressing the deficiency of the endogenous IL-36 receptor antagonist observed in patients, thereby improving their quality of life.
- Market Exclusivity: With orphan drug designation, Vanda will benefit from up to 10 years of market exclusivity and subsidies for research and development costs, significantly lowering its barriers to entry in the Japanese market and enhancing its profit potential.
- Stock Market Reaction: Vanda's stock closed up 3.86% at $6.46 on Wednesday, with after-hours trading showing a further increase of 1.24% to $6.54, reflecting positive market expectations regarding the drug's prospects.
See More
Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Vanda Pharmaceuticals will participate in three significant investor conferences in May 2026, including the Bank of America Securities Global Health Care Conference on May 12 in Las Vegas, showcasing its latest advancements in the biopharmaceutical sector to attract more investor interest.
- Conference Details: At the HCW 4th Annual BioConnect Investor Conference on May 19, Vanda will hold a fireside chat at 2:00 p.m. Eastern Time, expected to discuss the company's strategic direction and future development plans, thereby enhancing investor confidence.
- Live Streaming Access: Investors can access the fireside chat live on Vanda's corporate website during the HCW conference, emphasizing the company's commitment to transparency and investor relations by advising attendees to register and download necessary software 15 minutes prior to the event.
- Long-term Development Vision: Vanda Pharmaceuticals focuses on developing innovative therapies to address unmet medical needs, and participating in these conferences not only helps raise the company's profile but also lays the groundwork for its future commercialization strategy, driving sustained growth in the biopharmaceutical industry.
See More
